Compare QUALCOMM, Inc. (QCOM) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
QUALCOMM, Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? QUALCOMM, Inc. trades at $170.04 (market cap $188.86B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: QUALCOMM, Inc. is far larger — about 25.7× Spyre Therapeutics Inc. Common Stock's market cap, and QUALCOMM, Inc. pays a 2.08% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold QUALCOMM, Inc. for 87 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| QCOM | SYRE | |
|---|---|---|
Market Cap | $188.86B | $7.35B |
Volume | 12,280,716 | 1,624,631 |
Sector | Technology | Health |
52-Week High | $251.10 | $108.92 |
52-Week Low | $124.07 | $22.18 |
Typical Hold Time | 87 Days | 0 Days |
Enterprise Value | $195.82B | $6.35B |
Dividend Yield | 2.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Qualcomm trades at $176.96, up 1.45% today, with mixed technical signals showing bearish moving averages but oversold RSI readings. The company reported strong revenue of $44.28B in 2025 but net income declined to $5.54B, reflecting margin compression. Recent news highlights Qualcomm's strategic pivot toward AI and data center opportunities, including a potential $60B Amazon partnership that could diversify revenue streams beyond mobile chips.
Qualcomm presents a compelling risk-reward profile with analyst consensus target of $204.48 suggesting 15.5% upside. The company's expansion into AI/data center markets offers growth potential, but execution risks remain high as it navigates competition and the loss of Apple's modem business. Current valuation at 20.21 P/E appears reasonable if AI initiatives gain traction.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
